Vascular Biogenics

(NASDAQ: VBLT)
Healthcare  |  Biotechnology
1.13 -0.02 -1.74%
Stock Price | Nov. 20, 2019, 1:15 p.m.
0 Followers
Bid: 1.13
Ask: 1.15
Prev. Close: 1.15
52 Week Low: 0.6
52 Week High: 1.9
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 4/15/2015

4 years ago